Skip to content

Exploration of the clinical efficacy of Transcutaneous Acupoint Electrical Stimulation in the Treatment of Overactive Bladder

Exploration of the clinical efficacy of Transcutaneous Acupoint Electrical Stimulation in the Treatment of Overactive Bladder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001562
Enrollment
Unknown
Registered
2025-08-14
Start date
2024-12-17
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

control group:transcutaneous tibial nerve stimulation

Sponsors

Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 18-80 years gender not limited; (2) Meeting the diagnostic criteria for Overactive Bladder (OAB) according to the "2022 Version Chinese Diagnosis and Treatment Guidelines for Urological and Andrological Diseases"; (3) Disease course lasting more than 3 months; (4) Voluntarily participating in this clinical trial and signing the informed consent form; (5) After enrollment agreeing not to arbitrarily increase or decrease relevant medications affecting pelvic and lower urinary tract symptoms during the trial period; (6) Able to have good communication with the investigator and willing to comply with all requirements of the entire trial.

Exclusion criteria

Exclusion criteria: (1) Women who are pregnant or lactating; (2) Patients complicated with uncontrolled urinary tract infections urinary tract obstruction urological tumors interstitial cystitis or other diseases; (3) Patients with severe comorbidities significantly affecting health such as non-urinary malignant tumors; (4) Having received botulinum toxin treatment within the recent 12 months; (5) Those who have undergone sacral neuromodulation therapy; (6) Pelvic organ prolapse with POP-Q stage > II; (7) Participation in other clinical trials within 3 months prior to this trial; (8) Patients with psychiatric disorders unable to cooperate with physicians; (9) Judged by the investigator as unsuitable for this study or unable to comply with the study requirements.

Design outcomes

Primary

MeasureTime frame
Change in 24-hour micturition frequency from baseline to week 8 of treatment.;

Secondary

MeasureTime frame
Change in 24-hour micturition frequency from baseline to week 4 of treatment.;Change in 24-hour micturition frequency from week4 to week 8 of treatment.;urgency episodes;nocturia frequency;average urine volume;PPBC-S;AUA-SI-QOL ;OABSS;Proportion of subjects achieving a clinically meaningful improvement in OABSS score;

Countries

China

Contacts

Public ContactQiongqiong Liu /Ran Pang

Guang'anmen Hospital of Chinese Academy of traditional Chinese medicine

qqytkalb1@163.com18801379303

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026